No analyst coverage available for this stock.
AFT Pharmaceuticals Limited is a multinational pharmaceutical company focused on the development, marketing, and distribution of a wide range of pharmaceutical products. Founded in 1997 and headquartered in Auckland, New Zealand, the company maintains a diverse portfolio across multiple therapeutic categories, including allergy, gastrointestinal, pain management, digestive health, eye care, first aid, oral care, vitamins, and skin care. Its products are available through all major pharmaceutical channels, spanning over-the-counter, prescription, and hospital markets. AFT Pharmaceuticals' portfolio comprises both proprietary and in-licensed drugs, with a notable presence in patented, branded, and generic segments, allowing the company to serve various market needs and healthcare demands. With distribution agreements expanding its reach to over 40 countries, the company is recognized for its strong regional footprint in Australasia and its growing international presence. AFT Pharmaceuticals also emphasizes innovation and collaboration in its drug development initiatives, including partnerships to advance new therapies such as injectable treatments for iron deficiency. Its sustained growth has secured a significant role in the healthcare sector, meeting evolving patient and clinical requirements across global markets.